Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor

Raposeiras‐Roubín, Sergio; Abu‐Assi, Emad; Muñoz-Pousa, Isabel; Cespón‐Fernández, María; Paz, Rafael Cobas; Caneiro‐Queija, Berenice; López-Rodríguez, Elena; Perez-Casares, Luis; Jamhour-Chelh, Karim; Castiñeira-Busto, María; Barreiro-Pardal, Cristina; Calvo-Iglesias, Francisco; Íñiguez‐Romo, Andrés

doi:10.1016/j.thromres.2018.12.014

Cited by 15 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The smaller prevalence in our study could be attributed to the difference in the study population between our study and the previous study (i.e., ACS only vs. ischemic heart disease including acute and chronic coronary syndrome, respectively). Another singlecenter prospective study of 1,819 patients with ACS showed a cancer prevalence of 3.4%, 8 and a retrospective study including 6,068 patients showed a prevalence of 9.6%, 26 which is almost consistent with the result of our study.…”

Section: Discussionsupporting

confidence: 91%

Risk Prediction Score for Cancer Development in Patients With Acute Coronary Syndrome

Ishii

Marume

Nakai

et al. 2024

Circ J

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Risk Prediction Score for Cancer Development in Patients With Acute Coronary Syndrome

Ishii

Marume

Nakai

et al. 2024

Circ J

View full text Add to dashboard Cite

show abstract

“…Also concerning ticagrelor, PEGASUS-TIMI 54 trial showed an enhanced cancer risk of ticagrelor administered beyond 1 year, whereas PLATO was negative [152,178,179]. Interestingly Raposeiras-Roubin et al performed a retrospective study on 4229 consecutive acute coronary syndrome patients with a median follow up of 46 months [140]. They found that ticagrelor resulted in a lower cancer risk than clopidogrel without difference between clopidogrel and prasugrel.…”

Section: Are Anti P2y 12 Agents Protective or At Risk For Increased Cmentioning

confidence: 99%

P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation

Gaussem

Bachelot‐Loza

Nesseler

et al. 2020

IJMS

View full text Add to dashboard Cite

The P2Y12 receptor is a key player in platelet activation and a major target for antithrombotic drugs. The beneficial effects of P2Y12 receptor antagonists might, however, not be restricted to the primary and secondary prevention of arterial thrombosis. Indeed, it has been established that platelet activation also has an essential role in inflammation. Additionally, nonplatelet P2Y12 receptors present in immune cells and vascular smooth muscle cells might be effective players in the inflammatory response. This review will investigate the biological and clinical impact of P2Y12 receptor inhibition beyond its platelet-driven antithrombotic effects, focusing on its anti-inflammatory role. We will discuss the potential molecular and cellular mechanisms of P2Y12-mediated inflammation, including cytokine release, platelet–leukocyte interactions and neutrophil extracellular trap formation. Then we will summarize the current evidence on the beneficial effects of P2Y12 antagonists during various clinical inflammatory diseases, especially during sepsis, acute lung injury, asthma, atherosclerosis, and cancer.

show abstract

“…Finally, a retrospective registry study assessed the risk of de novo cancer diagnosis in acute coronary syndrome (ACS) patients discharged from a tertiary hospital with DAPT with either aspirin and clopidogrel, or aspirin and prasugrel, or aspirin and ticagrelor [79]. Among 4229 consecutive ACS patients, 311 were diagnosed with de novo cancer during a median follow-up of 46.2-months.…”

Section: The Chemoprotective Effect Of Other Antiplatelet Agentsmentioning

confidence: 99%

“…The cumulative incidence of cancer was 2.2 per 100 patients per year for clopidogrel users, compared to 1.6 per 100 patients per year for prasugrel users, and 0.3 per 100 patients per year for ticagrelor users. In multivariate and propensity score analyses, ticagrelor use was associated with a lower risk of de novo cancer diagnosis compared to clopidogrel or prasugrel use (adjusted HR 0.22; 95% CI 0.05–0.90; p = 0.036), regardless of DAPT duration [79].…”

Section: The Chemoprotective Effect Of Other Antiplatelet Agentsmentioning

confidence: 99%

Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies

Frère

Lejeune²,

Kubicek³

et al. 2019

Cancers

View full text Add to dashboard Cite

Over the past two decades, aspirin has emerged as a promising chemoprotective agent to prevent colorectal cancer (CRC). In 2016, the mounting evidence supporting its chemoprotective effect, from both basic science and clinical research, led the US Preventive Services Task Force to recommend regular use of low-dose aspirin in some subgroups of patients for whom the benefits are deemed to outweigh the risks. In contrast, data on the chemoprotective effect of aspirin against other cancers are less clear and remain controversial. Most data come from secondary analyses of cardiovascular prevention trials, with only a limited number reporting cancer outcomes as a prespecified endpoint, and overall unclear findings. Moreover, the potential chemoprotective effect of aspirin against other cancers has been recently questioned with the publication of 3 long-awaited trials of aspirin in the primary prevention of cardiovascular diseases reporting no benefit of aspirin on overall cancer incidence and cancer-related mortality. Data on the chemoprotective effects of other antiplatelet agents remain scarce and inconclusive, and further research to examine their benefit are warranted. In this narrative review, we summarize current clinical evidence and continuing controversies on the potential chemoprotective properties of antiplatelet agents against cancer.

show abstract

Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor

Cited by 15 publications

References 27 publications

Risk Prediction Score for Cancer Development in Patients With Acute Coronary Syndrome

Risk Prediction Score for Cancer Development in Patients With Acute Coronary Syndrome

P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation

Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies

Contact Info

Product

Resources

About